PUK14 Cost-Effectiveness Analysis of Mirabegron Versus Tolterodine Extended Release in the Treatment of Patients With Overactive Bladder in the United States
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1452
https://www.valueinhealthjournal.com/article/S1098-3015(12)03165-8/fulltext
Title :
PUK14 Cost-Effectiveness Analysis of Mirabegron Versus Tolterodine Extended Release in the Treatment of Patients With Overactive Bladder in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03165-8&doi=10.1016/j.jval.2012.08.1452
First page :
A457
Section Title :
Urinary/Kidney Disorders
Open access? :
No
Section Order :
949